Skip to main content

Invivyd, Inc.

IVVD
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001832038

No open-market purchases or sales by Invivyd, Inc. insiders were filed in the last 90 days; 125 institutions reported holding it in 13F filings for Q2 2026, worth $203.1M in total; Maverick Capital is the only superinvestor holding it.

Key figures

Market capClose on Nov 17, 2026
$151.5M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, −11 vs. previous quarter
125
13F valueReported value at the end of Q2 2026
$203.1M
Superinvestors holdingAt the end of Q2 2026
1

Price chart

From SEC filings, in USD.

Revenue, FY2025
$53.4M
+110.5% year over year
Net income, FY2025
-$52.5M
No comparable prior period
Free cash flow, FY2025
-$58.3M
No comparable prior period
Revenue, Q3 FY2026
$15.4M
+17.7% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $52.5M (98.2% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
36.2M
Shares sold short
Change
−842.1K
−2.3% vs. previous
Days to cover
9.66
At average daily volume

Superinvestors holding IVVD, Q2 2026

Go to the superinvestors tab

1 superinvestor reports holding Invivyd, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Maverick Capital

Lee Ainslie

0.1%

Invivyd, Inc.'s share of the portfolio

Shares
18,970,913
Value
$16.6M

Latest insider trades

See all insider trades

Open-market purchases and sales by Invivyd, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 18, 2026 (view filing)8:10 PM ETAug 17-181 dayLee Timothy EdwardChief Commercial OfficerSSale−40.8K$0.7766−$31.7K−18.6%178.9K after2 lots10b5-1
Aug 18, 2026 (view filing)8:10 PM ETAug 17-181 dayGreen JulieChief Human Resources OfficerSSale−40.8K$0.7766−$31.7K−19.4%168.9K after2 lots10b5-1
Aug 18, 2026 (view filing)8:10 PM ETAug 17-181 dayDuke William E.Chief Financial OfficerSSale−40.8K$0.7766−$31.7K−19.4%168.9K after2 lots10b5-1
Aug 18, 2026 (view filing)8:10 PM ETAug 17-181 dayAndersen JillChief Legal Officer, SecretarySSale−68.0K$0.7766−$52.8K−19.3%283.8K after2 lots10b5-1
Aug 18, 2026 (view filing)8:10 PM ETAug 17-181 dayAllen Robert D. IIIChief Scientific OfficerSSale−37.7K$0.7766−$29.3K−17.4%178.8K after2 lots10b5-1
Feb 18, 2026 (view filing)Feb 17-181 dayAllen Robert D. IIIChief Scientific OfficerSSale−37.6K$1.56−$58.7K−24.7%114.5K after2 lots10b5-1
Feb 18, 2026 (view filing)Feb 17-181 dayGreen JulieChief Human Resources OfficerSSale−40.6K$1.56−$63.4K−27.4%107.7K after2 lots10b5-1
Feb 18, 2026 (view filing)Feb 17-181 dayDuke William E.Chief Financial OfficerSSale−40.6K$1.56−$63.4K−27.4%107.7K after2 lots10b5-1
Feb 18, 2026 (view filing)Feb 17-181 dayLee Timothy EdwardChief Commercial OfficerSSale−40.6K$1.56−$63.4K−25.7%117.7K after2 lots10b5-1
Feb 18, 2026 (view filing)Feb 17-181 dayAndersen JillChief Legal Officer, SecretarySSale−67.7K$1.56−$105.7K−27.1%181.7K after2 lots10b5-1

Top 10 13F holders, Q2 2026

See all 125 holders

The largest institutional positions in Invivyd, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding IVVD in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Jupiter Topco LLC34,173,104$30.0M0.01%+34,173,104New
BVF Inc28,165,000$24.6M0.63%+8,640,000+44.3%Added
Maverick Capital LtdSuperinvestorMaverick Capital18,970,913$16.6M0.15%00.0%Unchanged
Perceptive Advisors LLC18,490,636$16.1M0.25%−2,368,667−11.4%Reduced
BlackRock, Inc.16,134,885$14.1M0.00%+11,853,095+276.8%Added
Vanguard Capital Management LLC10,496,507$9.15M0.00%+422,181+4.2%Added
M28 Capital Management LP9,248,250$8.07M17.11%00.0%Unchanged
Saturn V Capital Management LLC8,392,288$7.32M1.05%−2,556,796−23.4%Reduced
Soleus Capital Management, L.P.7,708,727$6.73M0.23%00.0%Unchanged
Point72 Asset Management, L.P.7,542,061$6.58M0.01%+7,498,130+17,068.0%Added

Holders of 5% or more of IVVD

See all 6 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Invivyd, Inc..

Largest holders of IVVD from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Janus Henderson Group PLC13G/A12.10%25.4M shares+0.50 ppfrom 11.60%Sep 8, 20252 filingsNov 14, 2025SEC
Biotechnology Value Fund L P13G/A9.99%29.6M shares+0.99 ppfrom 9.00%Oct 22, 20253 filingsAug 14, 2026SEC
Maverick Capital LtdSuperinvestorMaverick Capital13G/A8.30%24.4M shares+1.60 ppfrom 6.70%Feb 14, 20245 filingsNov 16, 2026SEC
Adimab, LLC13D/A7.30%20.3M shares−1.50 ppfrom 8.80%Mar 30, 20226 filingsDec 29, 2025SEC
Ra Capital Management, L.P.13G/A7.00%21.3M shares−2.90 ppfrom 9.90%Aug 29, 20253 filingsMay 15, 2026SEC